Nonsteroidal anti-inflammatory drugs are the most widely used medicine to treat pain, inflammation and to inhibit platelet function. Understanding the expression regulation of enzymes of the prostanoid pathway is of great medical relevance. Histone acetylation crucially controls gene expression. We set out to identify the impact of histone deacetylases (HDACs) on the generation of prostanoids and examine the consequences on vascular function.
Introduction
Prostanoids are important signaling molecules which are not only generated in the vascular system but also impact on several aspects of vascular biology. While some, such as prostacyclin (prostaglandin I 2 ) are predominantly endothelium-derived, other like prostaglandin E2 are also produced by vascular smooth muscle cells. Basically all physiologically generated prostanoids alter vascular tone, gene expression and proliferative state. Vascular prostaglandin production is limited by the expression of the key enzymes of the prostaglandin pathway and by the availability of arachidonic acid. Altering enzyme expression, therefore, importantly impacts on vascular prostaglandin production. Several of these genes are subject to conventional transcription control, for example by inflammatory transcription factors like NFκB. It is, however, also becoming obvious, that large parts of gene expression are controlled by epigenetic mechanisms, which are also important in vascular gene expression control (1, 2) Of these, histone modifications have a central role in controlling the chromatin structure.
Particularly, histone acetylations at lysine residues have a strong impact on gene transcription.
Acetylation transforms the condensed chromatin (heterochromatin) into a more relaxed structure (euchromatin) and thereby facilitates the access of the transcriptional machinery which results in increased gene transcription. The degree of acetylation on a lysine is dependent on the activity of histone acetyltransferases (HATs) and deacetylases (HDACs).
Both enzyme classes have fundamental roles in biological processes, cell fate decisions, maintenance, survival and cancer development and thus are potential drug candidates (3, 4) .
Especially, HDAC inhibitors (HDACi) have been introduced in the clinic as novel anti-cancer drugs. Vorinostat (SAHA) was the first HDACi approved by the United States Food and Drug Administration and is used for the treatment of cutaneous T-cell lymphoma.
HDACi also affects the vascular system. In experimental models, HDACi reduces angiogenesis, restenosis and vascular inflammatory activity (4) . HDACi also reduces endothelium-dependent relaxation as they reduce the expression of the endothelium nitric Whether HDACs impact on these enzymes in the vascular system is unknown and was studied here in the murine vasculature and human vascular smooth muscle cells. 
Materials and Methods

Materials
SAHA, apicidin, prostaglandin E2 and diclofenac were purchased from Sigma-Aldrich.
Arachchidonic acid and U46619 were from Cayman Chemical. Deta NONOate was acquired from Enzo Life Sciences. Antibody against H3K9ac (#C15410004), H3K27ac (#pAb-174-050) and RNAP2 (C15100055) were from Diogenode. Antibody against p300 was from Bethyl (#A300-358)
siRNA transfection
For siRNA treatment, smooth muscle cells (80-90% confluent) were transfected with Lipofectamine 3000 according to the instructions provided by Thermo Fisher Scientific. siRNAs for HDACs, p300 and control siRNAs (siScrambled/siSCRs) were purchased from Thermo Fisher Scientific (Stealth RNAi), siHDAC1 # HSS104725, siHDAC2 # HSS104728, siHDAC3 # HSS113050, siHDAC4 # HSS114673, siHDAC7 # HSS147499, siHDAC8 # HSS125194, siEP300-1 #HSS103259, siEP300-2 #HSS103258 siSCR1 # 12935-300 and siSCR2
#12935112.
Cell Culture
Human vascular smooth muscle cells (human aortic smooth muscle cells (HAoSMC), #354- supplemented with 8% fetal calf serum (FCS), penicillin (50 U/ml), streptomycin (50 μg/ml), EGF, FGF, glutamine and insulin from singlequots (PELOBiotech, Planegg, Germany). A humidified atmosphere of 5% CO2 at 37 °C was used. Cells were treated with SAHA 2 µmol/l or apicidin 200 nmol/l for 14 h in smooth muscle cell medium with 1% FCS.
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Organ Chamber Experiments
Male C57/BL6 mice (10 weeks of age) were obtained from Charles River Laboratories, Sulzfeld, Germany. Isometric tension recordings were performed in an organ chamber setup with murine carotid rings (1-2 mm) in Krebs Henseleit buffer containing 2.2 g/l glucose at 37 °C and 5% CO 2 . The concentration of the thromboxane receptor agonist U46619, used for preconstriction was adjusted to obtain an identical level of preconstriction (80%) relative to the contraction elicited by KCl (80 mmol/l). Arachidonic acid-induced relaxation was registered in the presence or absence of diclofenac 10 µmol/l.
Organ Culture
Murine carotid artery segments were dissected under sterile conditions, cleaned of adherent tissue, and incubated for 14 h under sterile conditions at 37°C in EBM culture medium containing 0.1% BSA, in the presence or absence of SAHA (2 µmol/l) in a conventional incubator at 5% CO 2 . Subsequently, the tissue was used for organ chamber experiments and molecular biology. 
Chromatin Immunoprecipitation (ChIP)
Preparation of cell extracts, crosslinking and isolation of nuclei was performed with the truCHIP™ Chromatin Shearing Kit (Covaris, USA) according to the manufacturers protocol.
The procedure was similar as described previously (9) . After sonification of the lysates with the Bioruptur Plus (10 cycles, 30 seconds on, 90 seconds off, 4°C; Diagenode, Seraing, Belgium), 
Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE)
FAIRE was performed similar as described (10, 11) . 2x10 6 VSMCs were crosslinked with 1% formaldehyde for 5 min and quenched with 125 mM glycine for 5 min. Afterwards, cells were scraped, washed with PBS and lysed in 2 mL FAIRE buffer 1 (50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) at 4°C for 10 min followed by centrifugation (5 min, 16,000 xg, 4°C). Cell pellets were resuspended and incubated in 2 ml FAIRE buffer 2 (10 mM Tris-HCl [pH 8.0], 200mM NaCl, 1 mM EDTA, 0.5 mM EGTA) for 10 min at 22°C followed by centrifugation (5 min, 16,000 xg, 4°C). Cell pellets were resuspended in 400 µl FAIRE buffer 3 (10 mM Tris-HCl, [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine). Samples were sheared (30 sec On, 90 sec Off, 10 cycles, 4°C) with a Bioruptor Plus (Diagenode) to an average length of 200-400bp. Subsequently, samples were cleared by centrifugation (5 min, 16,000 xg, 4°C). 10% of each sample was used as input. Samples were further extracted with phenol/chloroform/isoamylalcohol (Roti Phenol/C/I) and aqueous phase was collected. Input and extracted DNA were de-crosslinked at 65°C for 6 h, followed by DNA purification with the QIAquick PCR purification kit (QIAGEN).
ChIP-Sequencing
Chip-Sequencing data of p300 was obtained from ENCODE, track name HeLa-S3 EP300 and visualized by the Integrative Genomics Viewer (IGV) Version 2.3.81 (127).
LC-MS/MS
Sample analysis was performed using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). The LC-MS/MS system consisted of a hybrid triple quadrupole-ion trap QTrap 5500 mass spectrometer (Sciex, Darmstadt, Germany) equipped with a Turbo-V-source operating in negative ESI mode, an Agilent 1200 binary HPLC pump All quadrupoles were working at unit resolution. Quantitation was performed with Analyst Software V1.5 (Sciex, Darmstadt, Germany) using the internal standard method (isotopedilution mass spectrometry). Ratios of analyte peak area and internal standard peak area (yaxis) were plotted against concentration (x-axis) and calibration curves for each prostaglandin were calculated by least square regression with 1/concentration 2 weighting.
Statistics
Unless otherwise indicated, data are given as means ± standard error of mean (SEM).
Calculations were performed with Graphpad PRISM 5.0. For multiple group comparisons ANOVA followed by post hoc with Fisher LSD test was performed. In case of multiple testing, 
Results
Inhibition of HDACs reduces PGE 2 in the vasculature
To uncover the role of HDACs in the arachidonic acid metabolism, we determined the level of prostanoids in murine vessels incubated ex vivo with the HDAC inhibitor SAHA (2µmol/l, 14h).
Tandem mass spectrometry analysis revealed that the abundance of prostaglandin (PG) E2 was markedly decreased, whereas PGD 2 , thromboxane (TX) B 2 and 6-keto-PGF 1a , the marker for prostacyclin (PGI 2 ), were not affected by HDACi (Fig. 1) . Collectively, these findings suggest that HDAC activities are required for the PGE 2 levels in the vascular system.
PTGES1 expression is decreased by HDAC inhibition
The microsomal PGE 2 synthase (PTGES1) is the dominant enzyme responsible for the production of vascular PGE 2 from COX2-derived PGH 2 (12) . Because PGE 2 levels were reduced by HDACi, we suspected that Ptges1 expression was also attenuated by SAHA, which was indeed the case ( Fig. 2A) . There was, in contrast, a trend towards a slight induction of Ptges2 und Ptges3, which, however, did not reach the significance level. Moreover, these enzymes are not relevant for vascular prostaglandin formation. Smooth muscle cells are the predominant cell type in the vasculature. Therefore, we studied PTGES1 expression in combination with HDACi in human vascular smooth muscle cells (VSMCs). Consistent with the data obtained in the mouse vessels, human VSMCs exposed to 2 µmol/L SAHA expressed a significant lower level of PTGES1 as compared to control treated cells (Fig. 2B) . Thus, our initial observation in murine carotid artery rings is also valid in human VSMCs. To determine whether reduction of PTGES1 was a result of reduced HDAC activity and not an unspecific effect of SAHA, a second inhibitor, apidicin was tested, which had a similar effect on PTGES1 expression (Fig. 2B) . SAHA and apicidin are both canonical inhibitors, and thus reduce the activity of HDACs class 1 and 2 (13) . To identify which HDAC is responsible for maintaining vascular PTGES1 expression, RNAi experiments were performed with two different control scrambled siRNAs. However, knockdown of several HDACs reduced PTGES1 (Fig. 2C) , 
Inhibition of HDACs attenuates arachidonic acid -induced vessel relaxation
To determine the relevance of HDAC-mediated PTGES1 induction, vascular reactivity assays were performed. Mice lacking Ptges1 exhibit an impaired conversion of arachidonic acid to the vasodilator PGE 2 , without changes in the level of other prostanoids (12, 14, 15) . Therefore, we exposed preconstricted murine carotid rings to arachidonic acid as well PGE 2 as positive control and analyzed their subsequent relaxation. The carotid vessels responded to PGE 2 with relaxation (Fig. 3A) . In line with the diminished Ptges1 expression after HDACi, the arachidonic acid-induced relaxation was attenuated by SAHA preincubation (Fig. 3B) . Importantly, neither the relaxation to the NO donor DETA-NONOate nor the constriction to the thromboxane A2 receptor agonist U46619 was affected by HDACi (Fig. 3C&D) . In order to demonstrate that an attenuated formation of vasodilator prostaglandins but not unrelated effects of arachidonate are responsible for the reduced relaxation after HDACi, experiments were performed in the presence of the cyclooxygenase inhibitor diclofenac. Importantly, diclofenac attenuated the relaxation to arachidonic acid in vessels of the control group but did not attenuate responses in vessels of the SAHA group. Thus, attenuated metabolism of arachidonic acid to a vasodilator compound is responsible for the HDACi effect (Fig. 3B) . These data indicate that reduced HDAC activity in the vascular system attenuates arachidonic acid-induced relaxation, which could be attributed in part to decreased expression of PTGES1.
Inhibition of HDAC abolishes p300 binding to the PTGES1 gene
Histone acetylation is regulated by the competing activities of HDACs and histone acetyltransferases (HAT). The fact that PTGES1 expression was reduced by HDACi was unexpected. Since a direct action of HDACi should rather increase the acetylation of the PTGES1 gene and thus induce its expression. As this was obviously not the case for PTGES1, alternative modes of expression control were sought. For some genes HDACi decreases rather by guest, on August 28, 2017 www.jlr.org Downloaded from 13 than increases target acetylation (16, 17) but the mechanism underlying this effect is unclear.
Potentially, HDACi attenuates HAT expression and thereby recruitment to its target genes (17) .
We therefore determined whether or not HDACi affects the recruitment of the transcriptional activators HATs. Chromatin immunoprecipitation (ChIP)-Seq data from ENCODE for a putative binding of HATs (GCN5, PCAF and p300) suggest that the PTGES1 gene is particularly occupied by the p300 HAT (Fig. 4A) . Depletion of p300 by RNAi reduced PTGES1 expression in VSMCs, demonstrating that this HAT is indeed important for PTGES1 expression control (Fig 4B) . Moreover, also in our hands, p300 binding to the PTGES1 gene was observed by ChIP (Fig. 4C) . In accordance with our hypothesis of an attenuated HAT recruitment of HDACi, p300 abundance at the PTGES1 gene was largely attenuated after HDACi. (Fig. 4C) . For these experiments the HDACi apicidin was used due to its higher potency. In line with a previous report (18) , the reduced recruitment of p300 to the PTGES1 gene resulted in a reduced acetylation of the histone mark H3K27 but not H3K9 (Fig. 4D) . Importantly, these effects were specific for the exon 1 of PTGES1 and not observed for the PTGES1 promotor: A strong enriched binding of p300 was not observed 500 and 1000 bp upstream of PTGES1 TSS and H3K27 at this region was rather induced (Fig. 4D) .
HDACi not only attenuated acetylation of the PTGES1 exon 1 at H3K27, it also dramatically increased acetylation of H3K9 particularly in the promoter region (Fig. 4D) . H3K9ac is an active mark and thus should result in PTGES1 expression. Thus, only direct determination of the chromatin state (i.e. hetero vs. euchromatin) can unravel the chromatin situation around the PTGES1 gene. For this purpose, a formaldehyde-assisted isolation of regulatory element (FAIRE) assay was carried out. In accordance with the reduced p300 binding and H3K27ac, more closed chromatin in the PTGES1 exon 1 and more open chromatin in the promoter region was observed (Fig. 4E) . Finally, we addressed whether this closed chromatin environment could affect RNA polymerase 2 (RNAP2) occupancy. As recently, it was reported that HDACi can cause a block in the elongation step of transcription by pausing of RNA polymerase 2 (RNAP2) (19) . In line with this hypothesis, we observed a dramatic accumulation of RNAP2 within the first exon of Ptges1 (Fig. 4F) . Collectively, these findings suggest that the enzymatic activities of HDACs are required for proper binding of the transcription activator p300 to the PTGES1 gene to facilitate H3K27ac and thereby euchromatin to enables proper RNAP2 elongation.
Discussion
In this study we determined the role of HDACs in some aspect of vascular arachidonic acid metabolism. Inhibition of HDACs reduced vascular PGE 2 levels in the murine vasculature and in human vascular smooth muscle cells. This effect was a consequence of a reduced p300 recruitment to the Ptges1 gene. Here we observed that HDACi reduced vascular PGE 2 level in the carotid which resulted in attenuated arachidonic acid-induced relaxation suggesting an attenuated conversion of arachidonic acid to the vasodilator PGE 2 (12, 14, 15) . The role of PGE 2 in the control of the systemic blood pressure is under debate. Infusion of PGE 2 into the kidney commonly causes renal vasodilation (20) and mice lacking PTGES1 exhibit an exaggerated hypertensive response to angiotensin II under normal conditions but not in a hyperlipidemic situation (20, 21, 23) . In murine aortic rings, PGE 2 directly induces relaxation through the E-prostanoid (EP) 15 acetylation at certain sites. Indeed, recently two reports mediating HDACi with trichostatin A (TSA) and SAHA suggested that this can be the case in myocytes and endothelial cells (16, 17) . Apparently, a similar mechanism is operative in the present study for PTGES1 in VSMCs.
Gene set enrichment analysis (GSEA) of RNA-Seq suggested that HATs could be influenced by HDACi. Particularly, reduced gene expression of p300-dependent genes were observed as a result of decreased p300 recruitment in TSA treated cells (17) . Consistent with this, we observed that p300 occupancy to PTGES1 was also HDAC dependent. In fact, it was quite remarkable that acetylation of H3K27 a well-established target of p300 was strongly reduced by HDACi (24) . In line with this, Jin et al. reported that deletion of GCN5/PCAF, a different HAT, specifically reduces acetylation on histone H3K9 while deletion of p300 specifically reduced acetylation on H3K27 (18) . This suggests that due to the selective reduction in the recruitment of p300 the H3K27 but not the H3K9ac was decreased in response to HDACi. It is certainly unusual that such an epigenetic modification selectively occurs only in the PTGES1 gene especially in the first exon but not in the promoter. However, global run-on sequencing (GRO-seq) revealed that SAHA inhibit transcription of several genes by blocking RNAP2 elongation in the gene body (19) . The analysis indicated that repressed genes by HDACi have an impediment within the gene locus. We hypothesize that such an impediment within the gene body could be achieved by changing the H3K27ac level and thus the chromatin environment into a tight state, which results in accumulation of RNAP2. Indeed, such mechanism e.g. is operating by co-transcriptional RNA spicing, histone acetylation is frequently used to accumulate RNAP2 and the spicing machinery over alternative exons (19, 25, 26) In conclusion, HDACi results in decreased PTGES1 expression and vascular prostaglandin E2 formation as a consequence of attenuated recruitment of p300 to the PTGES1 gene. 
